Applied DNA Net Worth
Applied DNA Net Worth Breakdown | APDN |
Applied DNA Net Worth Analysis
Applied DNA's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Applied DNA's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Applied DNA's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Applied DNA's net worth analysis. One common approach is to calculate Applied DNA's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Applied DNA's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Applied DNA's net worth. This approach calculates the present value of Applied DNA's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Applied DNA's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Applied DNA's net worth. This involves comparing Applied DNA's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Applied DNA's net worth relative to its peers.
Enterprise Value |
|
To determine if Applied DNA is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Applied DNA's net worth research are outlined below:
| Applied DNA Sciences generated a negative expected return over the last 90 days | |
| Applied DNA Sciences has high historical volatility and very poor performance | |
| Applied DNA Sciences has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 3.43 M. Net Loss for the year was (7.09 M) with profit before overhead, payroll, taxes, and interest of 1.55 M. | |
| Applied DNA Sciences currently holds about 4.68 M in cash with (13.71 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.36. | |
| Latest headline from finance.yahoo.com: Applied DNA Sciences Fiscal Q3 Earnings Snapshot |
Applied DNA uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Applied DNA Sciences. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Applied DNA's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 8th of February 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 5th of December 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 30th of September 2023 Last Financial Announcement | View |
Applied DNA Target Price Consensus
Applied target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Applied DNA's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| One | Hold |
Most Applied analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Applied stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Applied DNA Sciences, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationApplied DNA Target Price Projection
Applied DNA's current and average target prices are 3.91 and 1.50, respectively. The current price of Applied DNA is the price at which Applied DNA Sciences is currently trading. On the other hand, Applied DNA's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Target Price
Analyst Consensus On Applied DNA Target Price
Know Applied DNA's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Applied DNA is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Applied DNA Sciences backward and forwards among themselves. Applied DNA's institutional investor refers to the entity that pools money to purchase Applied DNA's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Advisor Group Holdings, Inc. | 2025-03-31 | 2.0 | Royal Bank Of Canada | 2025-03-31 | 2.0 | Mccormack Advisors International | 2025-03-31 | 2.0 | Wealth Preservation Advisors | 2025-03-31 | 1.0 | Country Trust Bank | 2025-03-31 | 1.0 | Westside Investment Management, Inc. | 2025-06-30 | 1.0 | Org Partners Llc | 2025-03-31 | 1.0 | Activest Wealth Management | 2025-06-30 | 1.0 | Goldman Sachs Group Inc | 2025-03-31 | 0.0 | Anson Funds Management Lp | 2025-03-31 | 210.1 K | Ubs Group Ag | 2025-03-31 | 34.7 K |
Follow Applied DNA's market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 2.03 M.Market Cap |
|
Project Applied DNA's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (63.57) | (66.75) | |
| Return On Capital Employed | (63.57) | (60.39) | |
| Return On Assets | (63.57) | (60.39) | |
| Return On Equity | (63.57) | (60.39) |
When accessing Applied DNA's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Applied DNA's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Applied DNA's profitability and make more informed investment decisions.
Evaluate Applied DNA's management efficiency
Applied DNA Sciences has return on total asset (ROA) of (0.7341) % which means that it has lost $0.7341 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.4866) %, meaning that it created substantial loss on money invested by shareholders. Applied DNA's management efficiency ratios could be used to measure how well Applied DNA manages its routine affairs as well as how well it operates its assets and liabilities. As of the 17th of August 2025, Return On Tangible Assets is likely to drop to -66.75. In addition to that, Return On Capital Employed is likely to grow to -60.39. At this time, Applied DNA's Non Current Assets Total are very stable compared to the past year. As of the 17th of August 2025, Intangible Assets is likely to grow to about 2.6 M, while Total Assets are likely to drop about 7.7 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.03 | 0.03 | |
| Tangible Book Value Per Share | 0.03 | 0.03 | |
| Enterprise Value Over EBITDA | -2.1 M | -2 M | |
| Price Book Value Ratio | 135.3 M | 142 M | |
| Enterprise Value Multiple | -2.1 M | -2 M | |
| Price Fair Value | 135.3 M | 142 M | |
| Enterprise Value | 18.3 B | 17.3 B |
Management at Applied DNA Sciences focuses on leveraging technology and optimizing operations. We evaluate the impact of these focuses on the company's financial health and stock performance.
Enterprise Value Revenue 0.8781 | Revenue | Quarterly Revenue Growth 0.058 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Applied DNA insiders, such as employees or executives, is commonly permitted as long as it does not rely on Applied DNA's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Applied DNA insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Applied DNA time-series forecasting models is one of many Applied DNA's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Applied DNA's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Applied DNA Earnings Estimation Breakdown
The calculation of Applied DNA's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Applied DNA is estimated to be -20.625 with the future projection ranging from a low of -20.625 to a high of -20.625. Please be aware that this consensus of annual earnings estimates for Applied DNA Sciences is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-20.62 Lowest | Expected EPS | -20.62 Highest |
Applied DNA Earnings Projection Consensus
Suppose the current estimates of Applied DNA's value are higher than the current market price of the Applied DNA stock. In this case, investors may conclude that Applied DNA is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Applied DNA's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 30th of September 2026 | Current EPS (TTM) | |
| 1 | 59.56% | -33.4182 | -20.625 | 3730.95 |
Applied DNA Earnings History
Earnings estimate consensus by Applied DNA Sciences analysts from Wall Street is used by the market to judge Applied DNA's stock performance. Investors also use these earnings estimates to evaluate and project the stock performance into the future in order to make their investment decisions. However, we recommend analyzing not only Applied DNA's upcoming profit reports and earnings-per-share forecasts but also comparing them to our different valuation methods.Applied DNA Quarterly Gross Profit |
|
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Applied DNA's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Applied DNA Earnings per Share Projection vs Actual
Actual Earning per Share of Applied DNA refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Applied DNA Sciences predict the company's earnings will be in the future. The higher the earnings per share of Applied DNA, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Applied DNA Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Applied DNA, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Applied DNA should always be considered in relation to other companies to make a more educated investment decision.Applied Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Applied DNA's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-06-30 | 2025-06-30 | -37.5 | -33.4182 | 4.0818 | 10 | ||
2025-05-08 | 2025-03-31 | -3 | -15.3924 | -12.3924 | 413 | ||
2025-02-06 | 2024-12-31 | -0.33 | -0.5616 | -0.2316 | 70 | ||
2024-12-05 | 2024-09-30 | -0.35 | -0.307 | 0.043 | 12 | ||
2024-08-08 | 2024-06-30 | -0.35 | 0.47 | 0.82 | 234 | ||
2024-05-10 | 2024-03-31 | -4.5 | -5.31 | -0.81 | 18 | ||
2024-02-08 | 2023-12-31 | -0.31 | -0.09 | 0.22 | 70 | ||
2023-12-07 | 2023-09-30 | -0.27 | -0.26 | 0.01 | 3 | ||
2023-08-10 | 2023-06-30 | -0.24 | -0.24 | 0.0 | 0 | ||
2023-05-11 | 2023-03-31 | -0.2 | 0.05 | 0.25 | 125 | ||
2023-02-09 | 2022-12-31 | -0.29 | -0.3 | -0.01 | 3 | ||
2022-12-14 | 2022-09-30 | -0.26 | -0.01 | 0.25 | 96 | ||
2022-08-11 | 2022-06-30 | -0.35 | -0.13 | 0.22 | 62 | ||
2022-05-12 | 2022-03-31 | -0.33 | -0.23 | 0.1 | 30 | ||
2022-02-10 | 2021-12-31 | -0.27 | -0.63 | -0.36 | 133 | ||
2021-12-09 | 2021-09-30 | -0.37 | -0.6 | -0.23 | 62 | ||
2021-08-12 | 2021-06-30 | -0.26 | -0.46 | -0.2 | 76 | ||
2021-05-13 | 2021-03-31 | -0.21 | -0.33 | -0.12 | 57 | ||
2021-02-11 | 2020-12-31 | -0.54 | -0.56 | -0.02 | 3 | ||
2020-12-17 | 2020-09-30 | -0.52 | -0.78 | -0.26 | 50 | ||
2020-08-06 | 2020-06-30 | -0.67 | -0.72 | -0.05 | 7 | ||
2020-05-14 | 2020-03-31 | -0.77 | -0.79 | -0.02 | 2 | ||
2020-02-06 | 2019-12-31 | -1.24 | -1.12 | 0.12 | 9 | ||
2019-12-12 | 2019-09-30 | -1.26 | -2.63 | -1.37 | 108 | ||
2019-08-13 | 2019-06-30 | -1 | -1.6 | -0.6 | 60 | ||
2019-05-09 | 2019-03-31 | -3.6 | -3.2 | 0.4 | 11 | ||
2019-02-07 | 2018-12-31 | -3.2 | -4.4 | -1.2 | 37 | ||
2018-12-13 | 2018-09-30 | -1.4 | -4.8 | -3.4 | 242 | ||
2018-08-13 | 2018-06-30 | -2 | -4.0 | -2.0 | 100 | ||
2018-05-03 | 2018-03-31 | -4.8 | -2.8 | 2.0 | 41 | ||
2018-02-08 | 2017-12-31 | -4.4 | -4.8 | -0.4 | 9 | ||
2017-12-15 | 2017-09-30 | -3.6 | -4.0 | -0.4 | 11 | ||
2017-08-10 | 2017-06-30 | -2.8 | -4.0 | -1.2 | 42 | ||
2017-05-11 | 2017-03-31 | -5.2 | -5.2 | 0.0 | 0 | ||
2017-02-09 | 2016-12-31 | -2.4 | -6.4 | -4.0 | 166 | ||
2016-12-06 | 2016-09-30 | -3.6 | -4.0 | -0.4 | 11 | ||
2016-08-11 | 2016-06-30 | -4.4 | -5.6 | -1.2 | 27 | ||
2016-05-12 | 2016-03-31 | -4.4 | -5.6 | -1.2 | 27 | ||
2016-02-10 | 2015-12-31 | -3.6 | -5.2 | -1.6 | 44 | ||
2015-12-14 | 2015-09-30 | -3.6 | -0.8 | 2.8 | 77 | ||
2015-08-10 | 2015-06-30 | -5.2 | -3.2 | 2.0 | 38 | ||
2015-05-11 | 2015-03-31 | -5.6 | -4.4 | 1.2 | 21 | ||
2015-02-09 | 2014-12-31 | -5.2 | -18.0 | -12.8 | 246 | ||
2011-05-16 | 2011-03-31 | -24 | -24.0 | 0.0 | 0 | ||
2010-12-15 | 2010-09-30 | -24 | -24.0 | 0.0 | 0 |
Applied DNA Corporate Management
| CPA CPA | Chief Officer | Profile | |
| Warren Pearlson | Sales Consultant | Profile | |
| Tony Benson | Managing EMEA | Profile | |
| Janice Meraglia | G VP | Profile | |
| JD Esq | Chief Development | Profile | |
| Joseph Magno | Sales Consultant | Profile | |
| MeiLin Wan | VP Sales | Profile |
Already Invested in Applied DNA Sciences?
The danger of trading Applied DNA Sciences is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Applied DNA is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Applied DNA. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Applied DNA Sciences is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Applied DNA Sciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Applied DNA's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Applied Dna Sciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Applied Dna Sciences Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Applied DNA Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in consumer price index. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Electronic Equipment, Instruments & Components space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Applied DNA. If investors know Applied will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Applied DNA listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 3.7 K | Revenue Per Share | Quarterly Revenue Growth 0.058 | Return On Assets | Return On Equity |
The market value of Applied DNA Sciences is measured differently than its book value, which is the value of Applied that is recorded on the company's balance sheet. Investors also form their own opinion of Applied DNA's value that differs from its market value or its book value, called intrinsic value, which is Applied DNA's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Applied DNA's market value can be influenced by many factors that don't directly affect Applied DNA's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Applied DNA's value and its price as these two are different measures arrived at by different means. Investors typically determine if Applied DNA is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Applied DNA's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.